Skip to Main Content

Author Details

Jamshid S Khorashad
Institute of Cancer Research
2006
70
26
PMIDPaper TitleJournal TitlePublished Year
36744544Germline predisposition to haematological malignancies: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group.Br J Haematol2023
37496024FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions.BMC Med Genomics2023
34780648MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis.Blood2022
35775708Coexistence of two missense mutations in the KRAS gene in adenocarcinoma of the lung: a possible indicator of poor prognosis.Pathologica2022
34997766Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?Br J Haematol2022
33022753Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy.Br J Haematol2021
33712704Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B.Oncogene2021
34638347Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis.Cancers (Basel)2021
34680203Genomic Abnormalities as Biomarkers and Therapeutic Targets in Acute Myeloid Leukemia.Cancers (Basel)2021
34027418SIRT5 IS A DRUGGABLE METABOLIC VULNERABILITY IN ACUTE MYELOID LEUKEMIA.Blood Cancer Discov2021
33368155TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.Br J Haematol2021
31537692Prolonged treatment-free remission in chronic myeloid leukemia patients with previous <i>BCR-ABL1</i> kinase domain mutations.Haematologica2020
33099473The KDR (VEGFR-2) Genetic Polymorphism Q472H and c-KIT Polymorphism M541L Are Associated With More Aggressive Behaviour in Astrocytic Gliomas.Cancer Genomics Proteomics2020
32734668A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia.Br J Haematol2020
32519342An ex vivo investigation of interactions between primary acute myeloid leukaemia and mesenchymal stromal cells yields novel therapeutic targets.Br J Haematol2020
31578694Molecular Monitoring of Chronic Myeloid Leukemia.Methods Mol Biol2020
31567705Applicability of Routine Targeted Next-generation Sequencing to Estimate Tumor Mutational Burden (TMB) in Patients Treated With Immune Checkpoint Inhibitor Therapy.J Immunother2020
30563936Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.Clin Cancer Res2019
31648319The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations.Blood Adv2019
31184233Blast crisis of chronic myeloid leukemia with plasmacytoid dendritic cell phenotype associated with a rare fusion transcript, e13a3 BCR-ABL1.Leuk Lymphoma2019
31232126The influence of salivary amylase on total amylase elevation in CML patients treated with TKI therapy: a case series of 3 patients.Leuk Lymphoma2019
31073075Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors.Haematologica2019
30923102MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia.Haematologica2019
28771682Development of artificial bone marrow fibre scaffolds to study resistance to anti-leukaemia agents.Br J Haematol2018
29588547Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective.Leukemia2018
29695605Alginate foam-based three-dimensional culture to investigate drug sensitivity in primary leukaemia cells.J R Soc Interface2018
28465516Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.Leukemia2017
28495914E14a2 <i>BCR-ABL1</i> transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy.Haematologica2017
26752680A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia.Leuk Lymphoma2016
26648538Age-related mutations and chronic myelomonocytic leukemia.Leukemia2016
27480386Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy.Leukemia2016
27467708Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia.Am J Hematol2016
25134459Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.Leukemia2015
26202934β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.Leukemia2015
25573989shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.Blood2015
25132497BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.Cancer Cell2014
23223358BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.Blood2013
23887971KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.Cancer Res2013
23904234What challenges remain in chronic myeloid leukemia research?Haematologica2013
23448894New concepts for CML clonality.Oncotarget2013
21844874KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.Leukemia2012
22231203BCR-ABL1 kinase domain mutations: methodology and clinical evaluation.Am J Hematol2012
21328433Duplex quantitative PCR for molecular monitoring of BCR-ABL1-associated hematological malignancies.Am J Hematol2011
22054732Selection of therapy: rational decisions based on molecular events.Hematol Oncol Clin North Am2011
21867560Advances in the treatment of chronic myeloid leukemia.BMC Med2011
21346253Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy.Blood2011
19833633Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.Haematologica2010
20833982Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.Blood2010
20739956Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype.Leukemia2010
20855863EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.Blood2010
  • 1 - 50 of 70

Recommended Authors

Samantha L Savage
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2016
Number of shared co-authors 17
Ann-Kathrin Eisfeld
The Ohio State University Comprehensive Cancer Center
Career Start Year 2011
Number of shared co-authors 4
Jennifer Dunlap
Oregon Health & Science University
Career Start Year 2008
Number of shared co-authors 10
Friedrich St??lzel
University Hospital TU Dresden
Career Start Year 2008
Number of shared co-authors 4
Felicitas Thol
Hannover Medical School
Career Start Year 2007
Number of shared co-authors 2
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 1
Rashmi Kanagal-Shamanna
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 6
Thomas Cluzeau
Universite Nice Cote d'azur, CHU de Nice
Career Start Year 2005
Number of shared co-authors 1
Sandra Otto
Career Start Year 2004
Number of shared co-authors 4
Ronan Swords
Oregon Health and Science University
Career Start Year 2004
Number of shared co-authors 12
Raphael Itzykson
Universite Paris Cite, INSERM, CNRS
Career Start Year 2004
Number of shared co-authors 3
Jean-Baptiste Micol
INSERM U7, Universite Paris-Saclay
Career Start Year 2004
Number of shared co-authors 2
Daniel A Pollyea
University of Colorado Division of Hematology
Career Start Year 2004
Number of shared co-authors 18
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 6
Christopher S Hourigan
and Blood Institute, National Institutes of Health
Career Start Year 2001
Number of shared co-authors 13
Elie Traer
Oregon Health & Science University
Career Start Year 1998
Number of shared co-authors 14
Farhad Ravandi
University of Texas M.D. Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 10
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Career Start Year 1997
Number of shared co-authors 5
Brian J P Huntly
University of Cambridge
Career Start Year 1996
Number of shared co-authors 3
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Career Start Year 1996
Number of shared co-authors 4
Bruno C Medeiros
AbbVie Inc.
Career Start Year 1996
Number of shared co-authors 13
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 6
Gautam Borthakur
MD Anderson Cancer Center
Career Start Year 1992
Number of shared co-authors 8
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1991
Number of shared co-authors 17
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 14
Claude Preudhomme
Lille University Hospital, INSERM UMR-S7, CNRS UMR9020, Lille University.
Career Start Year 1989
Number of shared co-authors 3
Soheil Meshinchi
Fred Hutchinson Cancer Research Centre
Career Start Year 1987
Number of shared co-authors 12
Richard M Stone
Dana Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 14
Neil P Shah
University of California San Francisco
Career Start Year 1985
Number of shared co-authors 10
Torsten Haferlach
Taussig Cancer Institute, Cleveland Clinic
Career Start Year 1983
Number of shared co-authors 9

Collaborators

Michael W Deininger
University of Utah Huntsman Cancer Institute
Co-authored papers 20
Thomas O'Hare
Huntsman Cancer Institute, University of Utah
Co-authored papers 15
Anna M Eiring
Texas Tech University Health Sciences Center at El Paso
Co-authored papers 15
Anthony D Pomicter
Huntsman Cancer Institute, University of Utah
Co-authored papers 14
Srinivas K Tantravahi
Huntsman Cancer Institute at the University of Utah.
Co-authored papers 9
Matthew S Zabriskie
University of Utah
Co-authored papers 8
Dongqing Yan
Inner Mongolia University
Co-authored papers 7
Brian J Druker
Oregon Health & Science University
Co-authored papers 6
Hannah M Redwine
Huntsman Cancer Institute, The University of Utah
Co-authored papers 5
Anna Senina
Huntsman Cancer Institute, The University of Utah
Co-authored papers 5
Phillip M Clair
Huntsman Cancer Institute, The University of Utah
Co-authored papers 4
Jonathan M Ahmann
Huntsman Cancer Institute, The University of Utah
Co-authored papers 4
Christopher A Eide
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 4
Hein Than
Singapore General Hospital
Co-authored papers 4
Anca Franzini
University of Utah
Co-authored papers 3
Amber D Bowler
Huntsman Cancer Institute, The University of Utah
Co-authored papers 3
Riccardo Baron
Co-authored papers 3
Stephen G O'Brien
Newcastle University
Co-authored papers 2
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Co-authored papers 2
Kikkeri N Naresh
Fred Hutchinson Cancer Research Center
Co-authored papers 2
Thoralf Lange
Hospital Weissenfels
Co-authored papers 2
Richard Moriggl
Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna
Co-authored papers 2
Junia V Melo
University of Adelaide
Co-authored papers 2
Diana Resetca
University of Toronto
Co-authored papers 2
Jorge Cortes
Georgia Cancer Center
Co-authored papers 2
Kim-Hien T Dao
Astex Pharmaceuticals
Co-authored papers 2
Mark Yandell
University of Utah
Co-authored papers 1
Clare Turnbull
Institute of Cancer Research
Co-authored papers 1
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 1
Julie A Reisz
University of Colorado Anschutz Medical Campus
Co-authored papers 1
Release 1.2